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Abstract: Wound healing is a complex physiological process that is controlled by a well-orchestrated
cascade of interdependent biochemical and cellular events, which has spurred the development of
therapeutics that simultaneously target these active cellular constituents. We assessed the potential of
Parrotia persica (Hamamelidaceae) in wound repair by analyzing the regenerative effects of its two
main phenolic compounds, myricetin-3-O-β-rhamnoside and chlorogenic acid. To accomplish this,
we performed phytochemical profiling and characterized the chemical structure of pure compounds
isolated from P. persica, followed by an analysis of the biological effects of myricetin-3-O-β-rhamnoside
and chlorogenic acid on three cell types, including keratinocytes, fibroblasts, and endothelial
cells. Myricetin-3-O-β-rhamnoside and chlorogenic acid exhibited complementary pro-healing
properties. The percentage of keratinocyte wound closure as measured by a scratch assay was
four fold faster in the presence of 10 µg/mL chlorogenic acid, as compared to the negative control.
On the other hand, myricetin-3-O-β-rhamnoside at 10 µg/mL was more effective in promoting
fibroblast migration, demonstrating a two-fold higher rate of closure compared to the negative
control group. Both compounds enhanced the capillary-like tube formation of endothelial cells in an
in vitro angiogenesis assay. Our results altogether delineate the potential to synergistically accelerate
the fibroblastic and remodelling phases of wound repair by administering appropriate amounts of
myricetin-3-O-β-rhamnoside and chlorogenic acid.
Keywords: wound healing; angiogenesis; P. persica; myricetin-3-O-β-rhamnoside; chlorogenic acid
1. Introduction
Wounds are the results of injuries to the skin and can be caused by burns, microbial insults,
diabetes, ischemia, and trauma [1,2]. Approximately 2% of the U.S. population is affected by
chronic non-healing wounds which, along with burn victims, totals nearly 8 million people [3].
Wound repair is controlled by the cross-talk of various cytokines, growth factors, and cell types,
including keratinocytes, fibroblasts, and endothelial cells [1,4]. Keratinocytes, the major epidermis
cell type, initiate re-epitalization, differentiation, and migration over the injured dermis to cover the
epithelial surface. Fibroblasts migrate toward the site of injury, proliferate, and establish an extracellular
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matrix to facilitate tissue reconstruction [5]. Endothelial cells are activated by signals expressed
from keratinocytes and fibroblasts, leading to migration into the site to form new capillaries [6–10].
Wound contraction occurs over time in association with myofibroblasts and fibroblasts, which generate
collagen and mature scars [11]. The process of wound healing can be delayed due to different agents,
such as bacterial infection or an over-production of reactive oxygen species (ROS) at the site of injury,
threatening live cells [12]. Using antioxidant and antibacterial agents may, therefore, improve the
wound healing process and offer additional tissue protection.
Significant progress has been made in the development of therapeutics for wound closure.
Commercial drugs include Regranex (Bercaplermin, recombinant platelet-derived growth factor
PDGF; Johnson & Johnson), silver-based products, such as Silvadene (King Pharmaceuticals), and
wound dressing gels [13–15]. The physiological process of wound healing is multi-factorial in
nature rather than modulated by a single cytokine or cellular phenomenon. Lowering the immune
response, the secretion of angiogenic growth factors, or targeting a single cellular constituent offers
limited success [16]. Rather, a multi-targeted approach to modulate the interdependencies of various
components of tissue regeneration is needed for clinical efficacy.
However, the development of treatments that exploit the complex network of processes involved
in wound healing remains difficult and has been met with limited success so far. Natural compounds
are known to interact with numerous molecular targets [17,18]. Additionally, their antioxidant,
anti-microbial, and anti-inflammatory properties have attracted many laboratories to use various
forms of natural compounds in wound treatment [19,20]. In this context, polyphenols and flavonoids
have received significant attention due to their effectiveness in the attenuation of skin disorders
and the reduction of healing time [21–24]. Researchers have variously attributed these results to
(i) the inhibition of ROS [25]; (ii) the interruption of the cascade of free radical reactions [26]; (iii) the
suppression of the inflammatory nuclear transcription factor kappa B (NF-κB) pathway [27]; (iv) the
stimulation of collagen and elastic synthesis [28]; and (v) the reduction in membrane fluidity of
bacterial cells [29].
Efforts to identify natural products with anti-inflammation and anti-bacterial properties
have led to the discovery of Parrotia persica (P. persica), a member of the “Witch-hazel” family
(Hamamelidaceae) [30,31]. This family contains 31 genera and more than 140 species with a broad
geographic distribution [20]. This tree species was discovered for the first time by Parrot’s group [32].
Ethnobotanical studies have referred to the traditional use of this plan to treat respiratory infections
and fevers. According to the literature, different extracts from the leaves of P. persica have shown
significant antibacterial activity. Among different types of extracts, methanol extract was demonstrated
to be the most potent. In addition, an analysis of the methanolic extract of P. persica revealed a high
content of phenolic compounds, as well as a high level of antioxidant activity [32]. Other species of
this family, specifically Hamamelis virginica, with a similar secondary metabolite profile to P. persica,
have been demonstrated to possess anti-aging and antioxidant properties, as well as pro-stimulatory
effects in keratinocytes [33–35]. The combination of these findings motivates our study to evaluate the
wound healing potential of P. persica.
In the present study, for the first time, we focused on the determination of the phytochemical
profile, as well as the in vitro wound healing potential of P. persica and its secondary metabolites.
Our results demonstrate the previously unknown complementary effects of caffeoylqunic acid (i.e.,
chlorogenic acid) and myricetin-3-O-β-rhamnoside in the acceleration of wound closure and vascular
tube formation using in vitro models of migration and angiogenesis. These findings reinforce the
clinical evidence in support of natural compounds used alone or in combination with synthetic drugs
for regenerative medicine.
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2. Results
2.1. Phytochemical Profiling of P. persica
The phytochemical profile of an ethyl acetate (EtOAc) extract of P. persica was analyzed by
HPLC coupled with photo diode array (PDA), evaporative light scattering detector (ELSD), and
electro spray ionization mass spectrometry (ESIMS) detectors. A chromatogram recorded at 280 and
320 nm, together with the ELSD trace and the ESIMS base peak chromatogram, is shown in Figure 1.
It revealed a complex pattern of peaks that were both UV active and ionizable in ESIMS in the negative
mode. A total of 25 compounds were detected (Table 1). Of these, 14 compounds were purified and
fully characterized, while the remaining 11 compounds were tentatively identified with the aid of
their molecular formula calculated from liquid chromatography time of flight mass spectrometry
(LC-TOFMS) data, and by a comparison with the literature [35–39]. Major compounds included
myricetin, kaempferol, and quercetin glycosides, as well as galloyl glucoses bearing up to fourteen
galloyl residues. Caffeic acid derivatives were found as minor compounds. The UV-visible spectra
(typical maxima at approx. 280 nm) and m/z values were characteristic for the presence of hydrolysable
tannins [40]. The ELSD trace chromatogram of the extract corresponded with the LC-UV-ESI-TOF-MS
profile, and the comparison demonstrated that tannins specifically showed that octagalloyl glucose
(peak 18), and flavonoids myricetin, quercetin, and kaempferol glycosides (peak 8, 13, and 14), were
the major compounds in the EtOAc extract. The chemical structures of unambiguously characterized
compounds are shown in Figure 2, and tentatively identified compounds are given in Table 1 [41].
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Table 1. List of compounds isolated and/or detected in the EtOAc extract of P. persica.
Peak tR (min) Compound UV-Vis λmax (nm) m/z [M−H]− m/z [M−2H]−2 HPLC-TOF-MS(negative) IdentificationMethod
1 3.0 Galloyl glucose 231, 279 331.0657 MS-UV,NMR
2 3.5 Astringenin 405.1172 MS-UV
3 4.5 3-O-Caffeoylquinic acid 325 353.0861 707.1710 MS-UV,NMR
4 5.0 Trigalloyl glucose 275 635.0850 465.0706 MS-UV
5 6.2 5-O Caffeoylshikimic acid 288, 320 335.0781 MS-UV,NMR
6 6.5 Myricetin-3-O-β-glucoside 261, 357 479.0836 316.0206 MS-UV,NMR
7 8.0 1,2,4,6-Tetragalloyl glucose 275, 220 787.0996 617.0808 MS-UV,NMR
8 9.3 Myricetin-3-O-β-rhamnoside 260, 352 463.0887 316.022 MS-UV,NMR
9 10.4 Quercetin 3-O-β-glucoside 266, 356 463.0896 MS-UV,NMR
10 11.3 Pentagalloyl glucose 211, 278 939.1110 769.0952 MS-UV,NMR
11 12.0 Kaempherol-3-O-rutinoside 593.1525 463.0879 MS-UV,NMR
12 12.8 Digallic acid 321.0258 MS-UV
13 13.5 Quercetin-3-O-β-rhamnoside 258, 352 447.0935 300.0237 MS-UV,NMR
14 13.5 Kaempferol-3-O-β-glucoside 447.0935 MS-UV,NMR
15 14.7 Hexagalloyl glucose 214, 278 1091.1195 939.1100, 769.0865, 637.0700 MS-UV
16 16.3 Heptagalloyl glucose 214, 275 1243.1278 621.0412 1091.1181, 939,1102, 769.0859 MS-UV
17 17.1 Kaempferol-3-O-β-rhamnoside 431.0960 MS-UV,NMR
18 18.4 Octagalloyl glucose 214, 276 1395.1373 697.0706 1243.1265, 1091.1175, 939.1093, 767.1083 MS-UV
19 20.4 Nonagalloyl glucose 214, 276 1547.1480 773.0742 1395.1372, 1243.1268, 1091.1167, 919.1177 MS-UV
20 21.0 Quercetin-3-(3,4,6 trigalloyl glucose) 919.1236 767.1121, 615.1005, 463.0889 MS-UV,NMR
21 22.1 Decagalloyl glucose 214, 276 1699.1581 849.0767 1547.1470, 1395.134, 1243.1254,1091.1146, 939.1083 MS-UV
22 23.7 Undecagalloyl glucose 214, 273, 305 925.0841 849.0778, 773.0715, 697.0648, 621.0590,545.0549, 469.0500 MS-UV
23 25.2 Dodecagalloyl glucose 214, 273, 305 1001.5901 925.0841, 849.0781, 773.0721, 697.654, 621.0580,545.0556, 469.0498 MS-UV
24 26.8 Tridecagalloyl glucose 214, 273, 305 1077.5907 1001.5907, 925.0847, 849.0779, 773.0731,697.0649, 621.0598, 545.0554, 469.0506 MS-UV
25 27.8 Tetradecagalloyl glucose 214, 273, 305 1153.6028 1077.5960, 1001.5898, 925.0832, 849.0781,773.0710, 697.0658, 621.0593, 545.0556, 469.0505 MS-UV
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2.2. Selective Stimulation of Cell Growth
We investigated the viability of a normal human keratinocyte (NHEK), normal human dermal
fibroblast (NHDF), and human umbilical vein endothelial (HUVEC) in the presence of two selected
pure compounds, myricetin-3-O-β-rhamnoside and chlorogenic acid, to determine the optimum
concentrations for subsequent ound healing assays. The results were compared to control groups
containing growth media, growth media plus dimethyl sulfoxide (DMSO), and growth media
containing varied concentrations of P. persica extract (Figure 3). The viability of NHEKs was slightly
concentration dependent with myricetin-3-O-β-rha noside, but no cell toxicity was seen for both
compounds in the concentration range of 10–100 µg/mL (Figure 3A).
The viability of NHDFs treated with chlorogenic acid and myricetin-3-O-β-rhamnoside
demonstrated a concentration dependent increase (10–50 µg/mL). Chlorogenic acid had a higher
proliferative effect when compared to myricetin-3-O-β-rhamnoside and the control groups (Figure 3B).
This was contrary to the pattern of HUVECs viability, indicating that the concentrations of 10 µg/mL
and 20 µg/mL of myricetin-3-O-β-rhamnoside were the most effective dosages for cell proliferation,
while 10 µg/mL was the most effective for HUVECs viability when exposed to chlorogenic acid
(Figure 3C). In all cell lines, exposure to the extract at different concentrations did not result in a marked
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increase in cell number. Our results demonstrate the nontoxic effects of the studied chlorogenic acid
and myricetin-3-O-β-rhamnoside on various cell lines, as well as their potential to induce proliferation.
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Figure 3. Effect of myricetin-3-O-β-rhamnoside (M), chlorogenic acid (C), and total extract of P. persica
(EX) on cell proliferation of (A) NHEKs; (B) NHDFs; and (C) HUVECs. Cell viability (%) was calculated
using an MTS assay after 24 h of exposure to various concentrations of the studied compounds.
No toxicity was observed in all three cell lines when compared to the control (untreated cells in growth
media) and vehicle control (untreated cells in growth media containing control DMSO). Multiple t-tests
were performed using Graph-Pad Prism 7.03 to determine the significance between each experimental
group and control (* p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001).
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2.3. Wound Healing Activity of Myricetin-3-O-β-Rhamnoside and Chlorogenic Acid
The ability of myricetin-3-O-β-rhamnoside and chlorogenic acid to accelerate the migration
of NHEKs and NHDFs was evaluated using the scratch assay. Figure 4 shows the percentage of
simulated wound closure over a time period of 20 h, at different time points of the assay, with two test
concentrations (10 and 20 µg/mL). Controls were carried out using growth media, and growth media
containing P. persica extract at a concentration of 50 µg/mL. Our results demonstrated that NHEKs
were most sensitive to chlorogenic acid, showing the highest level of wound closure (Figure 4A).
As early as 6 h, we observed approximately 40% of the gap to be closed with 10 µg/mL of chlorogenic
acid. A higher concentration of chlorogenic acid, however, did not lead to a faster migration rate.
Neither myricetin-3-O-β-rhamnoside nor P. persica extract led to a significantly higher NHEK gap
closure than the control.
The analysis of wound closure using NHDFs demonstrated a contrasting pattern when compared
to NHEKs (Figure 4B). Myricetin-3-O-β-rhamnoside at a concentration of 10 µg/mL accelerated gap
closure at all time points. The higher concentration of myricetin-3-O-β-rhamnoside, however, had
a negative effect on wound closure during early time points. Chlorogenic acid exhibited a delayed
effect on NHDF gap closure at 20 h post-seeding. Similar to NHEKs, the extract did not accelerate the
migration of NHDFs into the scratched gap when compared to the control. These results suggest a
complementary effect of the two compounds in our wound healing models.
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Figure 4. Wound closure percentage of (A) NHEKs and (B) NHDFs after different time intervals of
exposure to different concentrations of the natural compounds, as measured using a scratch assay.
Chlorogenic acid (C) and myricetin-3-O-β-rhamnoside (M) at 10 µg/mL demonstrated the highest
effect on the migration of NHEKs and NHDFs in closing the gap. Multiple t-tests were performed using
Graph-Pad Prism 7.03 to determine the significance between each experimental group and control
(* p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001). T-tests were performed to compare each pure compound
group to extract (# p ≤ 0.05, ## p ≤ 0.01 and ### p ≤ 0.001).
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2.4. Pro-Angiogenic Effects of Myricetin-3-O-β-Rhamnoside and Chlorogenic Acid
We used a capillary tube formation assay to quantify the potential stimulatory effects of
chlorogenic acid and myricetin-3-O-β-rhamnoside on angiogenesis. The compounds were studied at
two concentrations (10 and 20 µg/mL), and were added separately to HUVECs cultured on matrigels.
Cells were visualized at 8 h post-seeding. Figure 5 shows the average number of junctions of the
chlorogenic acid and myricetin-3-O-β-rhamnoside treated cultures compared to the control groups.
We observed marked changes in the cell patterns, with the formation of tubules assembled by
the elongation and joining of HUVECs in the presence of both myricetin-3-O-β-rhamnoside and
chlorogenic acid (Figure 5A). A quantitative analysis of the data showed that the effect was clearly
visible at 8 h when the number of junctions was approximately three-fold higher than in the control
groups (Figure 5B). The results indicate a pro-angiogenic activity of the pure compounds.
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microscopy of the vascular network; (B) The number of junctions after 8 h of treatment. Tubular 
network formation was significantly higher for both the myricetin-3-O-β-rhamnoside (M) and 
chlorogenic acid compounds compared to the control (non-treated cells in growth media) and extract. 
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Wound healing is comprised of a cascade of biochemical events that includes three main phases 
of inflammation, reepithelization, and tissue remodeling [42]. The majority of innovations in drug 
discoveries aim at expediting the healing process. Natural compounds have garnered significant interest 
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Figure 5. In vitro capillary tube formation of HUVECs treated in the absence or presence of
myricetin-3-O-β-rhamnoside (M), chlorogenic acid (C), or the total extract (EX) of P. persica. (A) Phase
contrast microscopy of the vascular network; (B) The number of junctions after 8 h of treatment.
Tubular network formation was significantly higher for both the myricetin-3-O-β-rhamnoside (M) and
chlorogenic acid compounds compared to the control (non-treated cells in growth media) and extract.
Multiple t-tests were performed using Graph-Pad Prism 7.03 to determine the significance between
each experimental group and control (*** p ≤ 0.001). T-tests were performed to compare each pure
compound group to extract (### p ≤ 0.001).
3. Discussion
Wound healing is comprised of a cascade of biochemical events that includes three main phases
of inflammation, re pitheliza ion, nd tissu remodeling [42]. The majority of innovations in drug
discoveries aim at expedi ing the he ling process. Natural compounds have garnered s gnificant
interest in drug discovery due to their multi-targ ting capability, as w ll as their antioxidant,
antibacterial, and anti-inflammatory prop rties [43,44]. In this context, reports hav demonstrated
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that flavonoids (e.g., kaempferol, quercetin) and their mixtures help accelerate wound closure
through a complex mechanism that involves inducing intercellular calcium-dependent pathways,
stimulating collegian deposition, and the suppression of cyclooxygenase-2 (COX-2) expression [45,46].
Phenolic compounds that consist of galloyl moieties (e.g., tannins) have also been shown to be effective
in wound repair and scar remodeling due to their ability to stimulate vascular formation [47,48].
In light of reports on the pharmaceutical applications of natural compounds belonging to the
Hamamelidaceae family as anti-inflammatory and anti-aging drugs [30,32], we set out to elucidate the
potential of P. persica and its main active metabolites to promote wound healing. When phytoprofiling
the species, we found 25 components, including several well characterized compounds of quercetin,
myricetin, and kaempherol. Interestingly, the analysis of tannin oligomers and sugar moieties in
P. persica revealed a rich diversity in tannins featuring three to 14 galloyl units. A comparison of
P. persica’s isolated compounds with another species of Hamamelidaceae, H. virginica, revealed a
similar phytoconstituent profile [35]. It is important to note that H. virginica was traditionally used by
Native Americans to treat burns and injuries [33].
The effectiveness of the Hamamelidaceae family is mainly attributed to its abundance of
flavonoids and phenols, as well as polysaccharides [33,35,37,49,50]. Therefore, we chosed two
under-examined polyphenol and flavonoid compounds isolated from P. persica, chlorogenic acid
and myricetin-3-O-β-rhamnoside. Chlorogenic acid is an ester of caffeic acid and quinic acid, which
has high bioavailability in nature [44]. Reports have shown the high potential of chlorogenic acid
as an antidiabetic, antihypertensive, antitumor, and anti-inflammatory agent in the prevention of
gastric lesions and hepatic injuries [51–53]. Caffeic acid phenetyl ester, a derivative of chlorogenic acid,
has also been shown to be effective in stimulating endothelial function and vascular hypertrophy in
hypertensive rats [54]. Myricetin-3-O-β-rhamnoside is effective in improving memory impairment in
mice through inhibiting acetylcholinesterase [55]. It is also an alternative multi-target antivirulence
candidate for controlling Staphylococcus aureus [56]. In addition, myricetin-3-O-β-rhamnoside prevents
the photo-damage of keratinocytes caused by UV radiation [57]. These results all together motivated us
to investigate the potential of chlorogenic acid and myricetin-3-O-β-rhamnoside isolated from P. persica
in stimulating NHEK and NHDF migration, as well as endothelial cell capillary tube formation.
Our in vitro experiments revealed a cell-specific and dose-dependent response to chlorogenic
acid and myricetin-3-O-β-rhamnoside. Both compounds in the range of 10–20 µg/mL were effective in
promoting cell growth. We observed NHEKs to be more sensitive to the chlorogenic acid concentration,
whereas the viability of endothelial cells responded more effectively to myricetin-3-O-β-rhamnoside.
Neither compounds included a toxic effect when we maximized the dose to 100 µg/mL. Cell migration,
as measured by a scratch assay, also showed variability in the cellular response to the two compounds.
We observed myricetin-3-O-β-rhamnoside to be effective in inducing the migration of NHDFs at early
time points. The mode of action was different for chlorogenic acid in that it promoted NHEK migration
at early time points. Nevertheless, both compounds effectively induced capillary tube formation at
a concentration of 10 µg/mL. The results suggest the role of these two polyphenol and flavonoid
compounds in different stages of the wound healing process with synergistic mechanisms.
The selective impact of each compound on specific cell lines can be attributed to the different
mechanisms by which flavonoids and polyphenols stimulate cells. It has been previously shown
that myricetin-3-O-β-rhamnoside regulates the activation of mitogen-activated protein kinases and
C-Jun N-terminal kinase [58]. Chlorogenic acid, however, regulates the secretion of collagens and
matrix metalloproteinases [59–61]. It is noteworthy that the final stage of wound healing is associated
with collagen secretion that regulates scar tissue formation. The most active cell types responsible in
this stage of wound healing include fibroblasts and myoblasts. These cells synthesize and remodel
the extracellular matrix (ECM), multiple forms of collagen, and matrix metalloproteinase (MMPs).
A significant challenge in would healing strategies is to orchestrate the cascade of events that
recapitulates the synthesis and remodeling of scar tissue formation. A clear advantage of natural
compounds compared to synthetic drugs is that they concurrently target multiple cellular phenomena.
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This is particularly important in complex regenerative therapies with various cellular constituents.
The complementary mode of action for myricetin 3-O-β-rhamnoside and chlorogenic acid is of
particular interest in this study. Further studies are warranted to explore the cell-specific mechanism
of action of the two compounds in co-culture, as well as in vivo conditions to define the biological
contribution and mechanism of action in a more realistic wound healing model. Deeper insight into the
mechanistic effects and cell signaling processes of these compounds will allow further control over cell
proliferation, migration, and angiogenesis, and will improve our ability to transfer the findings of this
study to clinical applications. The complex interactions of different cell types and signaling molecules
in the wound healing process is ignored in this study to establish the proof of concept. Future studies
should take into account these interactions in evaluating the efficacy of this strategy in vivo.
4. Materials and Methods
4.1. Chemicals and Solvents
HPLC grade water was obtained from an EASY-pure II (Barnstead, Dubuque, IA, USA) water
purification system. Analytical grade solvents including petroleum ether (PetEther), ethyl acetate
(EtOAc), and methanol (MeOH) for extraction and HPLC grade solvents including dimethyl sulfoxide
(DMSO), acetonitrile (MeCN), formic acid (HCOOH), and methanol for chromatography were
purchased from Scharlau (Barcelona, Spain). Solvents for nuclear magnetic resonance (NMR)
spectroscopy were obtained from Armar Chemicals (Döttingen, Switzerland). Sephadex LH-20 was
purchased from GE Healthcare (Fairfield, CT, USA).
4.2. Cell Culture and Reagents
HUVECs, NHEKs, NHDFs, and related media for cell cultures, including endothelial growth
medium-2 (EGM-2), keratinocyte growth medium-2 (KGM™-2), and fibroblast growth medium
(FGM™) were purchased from Lonza (Walkersville, MD, USA). Cells were incubated at 37 ◦C and 5%
CO2 throughout the experiment. Phosphate-buffered saline (PBS), a 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Promega) (Madison, WI, USA)
colorimetric assay, and growth factor reduced matrigel BD (Corning), (New York, NY, USA) were
purchased from Sigma-Aldrich (Milwaukee, WI, USA).
4.3. Instruments
NMR spectra were recorded using an Avance III™ spectrometer (Bruker BioSpin, Fällanden,
Switzerland) operating at 500.11 MHz for 1H and 125.77 MHz for 13C. Spectra were obtained
with a 1-mm TXI microprobe (1H- and 2D-NMR) and a 5-mm BBO probe with a z-gradient (13C).
Spectra were processed with Bruker TopSpin 3.0 software (Bruker BioSpin GmbH, Rheinstetten,
Germany). High resolution electrospray ionization mass spectrometry (HRESI-MS) spectra in negative
ion mode were recorded on a Bruker micro time of flight mass spectrometry (TOF ESI-MS) system
with a mass-to-charge ratio (m/z) scanning range of 150–1500. Mass calibration was performed with
isopropanol–water (1:1) containing 5mM sodium hydroxide. The typical mass accuracy was ±7 ppm.
HyStar 3.0 software (Bruker Daltonics, Bremen, Germany) was used for data acquisition and processing.
HPLC-PDA-ESIMS separations were performed on an 1100 series HPLC system (Agilent, Waldbronn,
Germany) consisting of a quaternary low-pressure mixing pump with a degasser module, column
oven, PDA detector, and auto sampler, coupled to an Esquire 3000 plus an ion trap mass spectrometer
with an electrospray interface (Bruker Daltonic, Bremen, Germany). HPLC-ELSD-PDA analysis was
performed on an Alliance 2695 instrument (Waters, Milford MA, USA) equipped with a 996 PDA
detector and a series 2000 evaporative light scattering detector (Alltech, Helsinki, Finland). The ELSD
conditions included a nitrogen flow of 2.5 L/min and temperature of 55 ◦C. ESIMS spectra were
recorded in the range of 150–1500 m/z in the negative mode.
Molecules 2017, 22, 1501 11 of 15
A P50 pump (GE Healthcare, Helsinki, Finland) and fraction collector (Pharmacia Biotech,
Piscataway, NJ, USA) were used for column chromatography on a Sephadex LH-20 column
(870 × 70 mm). Thin layer chromatography analysis was carried out on silica gel 60 F254 plates
(TLC) (Merck, Darmstadt, Germany), with EtOAc/MeOH/HCOOH (60/40/0.05% v/v/v) as the mobile
phase. Detection was at UV 254 and 366 nm. For all analytical HPLC analyses, samples were dissolved
in DMSO at 5 mg/mL, and 10 µL aliquots were injected. The mobile phase consisted of H2O and
MeCN containing 0.1% formic acid. The following gradient profile with a flow rate of 0.4 mL/min was
used for qualitative, LC-TOF, and ELSD analysis, starting with 20% of MeCN isocratic solution for
3 min and then an increasing gradient up to 35% MeCN over the next 3–20 min. This was followed
by a 20–30 min increase to 100% MeCN and then 5 min of an isocratic solution of 100% MeCN.
UV spectra were recorded in the range of 210–400 nm. SunFire®C18 (3.5 µm, 3.0 × 150 mm i.d.)
(Waters, Wexford, Ireland) and SunFire C18 (5 µm, 10 × 150 mm) columns (Waters) were used for
analytical and semi-preparative RP-HPLC separations, respectively. The column temperature was set
at 30 ◦C.
4.4. Extraction and Isolation
The dried leaves of P. persica were powdered (90 g) and percolated sequentially with petroleum
ether, EtOAc, MeOH, and H2O. An aliquot (7.2 g) of the EtOAc extract (17.4 g) was loaded on a
Sephadex LH-20 column, which was eluted with MeOH at a flow rate of 2.0 mL/min. The column
effluent was pooled according to TLC patterns to afford 16 fractions. A portion of fraction 7 (123 mg)
was separated by semi-preparative HPLC using a gradient of H2O/MeCN (containing 0.1% formic
acid) (80:20 to 100:0 over 25 min) at a flow rate of 4 mL/min to afford compounds 12 (4 mg, retention
time (tR) 5.07 min), 6 (4.9 mg, tR 8.13 min), 8 (25 mg, tR 9.95 min), 13 (1.6 mg, tR 12.76 min), and 11
(0.7 mg, tR 17.79 min).
Fraction 5 (95 mg) was separated by semi-prep HPLC using a gradient of H2O/MeCN 0.1% formic
acid (80:20 to 100:0 over 25 min) at a flow rate of 4 mL/min to afford compounds 8 (4.5 mg, tR 9.71 min),
9 (2.7 mg, tR 10.34 min), 13 (37 mg, tR 11.61 min), and 17 (1.4 mg, tR 15.80 min). Fraction 13 (49 mg) was
separated in the same manner to yield compounds 1 (3 mg, tR 3.49 min) and 3 (13.2 mg, tR 6.09 min).
Fraction 14 (24.8 mg) afforded gallic acid (8 mg, tR 3.32 min). Fraction 15 (26.6 mg) produced compounds
5 (1 mg, tR 12.1 min), 14 (9 mg, tR 14.78 min), and 17 (2 mg, tR 15.89 min). Fraction 16 (100 mg) afforded
compounds 7 (1.6 mg, tR 10.94 min), 10 (18 mg, tR 11.59 min), and 20 (2.3 mg, tR 24.51 min).
4.5. Analysis of Cell Viability
HUVECs, NHDFs, and NHEKs were cultured in their respective growth media to reach 80%
confluency. Cells were seeded at a density of 5 × 103 cells per well into a 96 well plate, and incubated
for 24 h at 37 ◦C and 5% CO2 to allow for cell attachment. Media was changed and replaced with
media supplemented with the desired concentration of test compounds (10, 20, 50, 100 µg/mL).
For that purpose, stock solutions of compounds at 10 mg/mL in DMSO were diluted in culture media.
The vehicle control was culture medium supplemented with 0.5% DMSO, representing the highest
final concentration of DMSO used to dissolve the test compounds.
To assess cell viability following the 24 h incubation period, media containing 20% MTS solution
was replaced with cell growth media, and cells were incubated for 2 h. The absorbance of formazan was
measured at 490 nm using a Spectramax 190 spectrophotometer (Spectramax, Sunnyvale, CA, USA).
4.6. In Vitro Scratch Assay
Cell migration of different cell lines was assessed by making a scratch on confluent monolayers
of NHDFs and NHEKs. Briefly, a total of 15 × 104 cells per well were seeded on a 24 well plate and
left overnight. Cells were given 24 h to attach and reach confluency. The cell layer was then scraped
using a 200 µL pipet tip and any cell debris was washed away with PBS. The samples were then
supplemented with different concentrations of compounds of interest in growth media followed by
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incubation in a 37 ◦C temperature and 5% CO2 controlled incubator. Images were taken every 4 h
using a phase contrast Nikon Eclipse Ti-E inverted microscope. Quantification of the cell migration
across the scratch to simulate wound closure was performed using the following formula:
Wound closure % = W0 −Wn/W0
in which Wn is the width of the gap and W0 is the initial width right after creating the scratch.
4.7. Capillary Tube Formation
An in vitro tube formation assay was performed using HUVECs cultured on matrigel. A total of
50 µL of matrigel was added to each well of a pre-chilled 96-well plate and then incubated for 30 min
at 37 ◦C to form a gel. Next, 100 µL of HUVEC cell suspension in media (20,000 cells/well) containing
chlorogenic acid and myricetin-3-O-β-rhamnoside was added to the gels and incubated at 37 ◦C for
8 h [62]. The number of branch sites/nodes in vascular tubes was examined using a phase contrast
inverted microscope (Invitrogen EVOS FL Auto Cell Imaging, Waltham, MA USA) and compared to
the samples in which no compounds were added (i.e., the negative controls).
4.8. Statistical Analysis
Three samples (n = 3) were analyzed per condition unless otherwise stated. All data were
statistically presented as the mean ± standard error. Multiple t-tests were performed using Graph-Pad
Prism 7.03 (La Jolla, CA, USA) to determine the significance between each experimental group. P values
less than 0.05 were considered to be significant.
5. Conclusions
In this study, for the first time, we analyzed the phytochemical structure of P. persica and
its potential clinical application in the treatment of skin injuries. We found the majority of
identified compounds to be tannin oligomers of three to tetradecagalloyl glucose and polyphenols.
The identification of tannins with more than 10 galloyl moieties is rare among plants of this genus.
The presence of these molecules confers strong antibacterial properties to P. persica, suggesting
potential clinical use in wound regeneration applications. The in vitro analysis of the two abundant
flavonoid and polyphenol molecules in P. persica, chlorogenic acid, and myricetin-3-O-β-rhamnoside,
demonstrated the effective promotion of wound closure and capillary tube formation. Strikingly, the
two compounds exhibited a complementary effect in that myricetin-3-O-β-rhamnoside accelerated
fibroblast migration, whereas chlorogenic acid enhanced keratinocyte wound closure. Further studies
are warranted to determine the mechanisms of action and clinical doses of these compounds using
appropriate in vivo models.
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